

**Synonym**

TNFRSF17,CD269,BCM,BCMA

**Source**

PE-Labeled Human BCMA, His Tag (BCA-HP2H7) is produced via conjugation of PE to Human BCMA, His Tag with a new generation site-specific technology under Star Staining labeling platform. Human BCMA, His Tag is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ala 54 (Accession # [Q02223-1](#)).

Predicted N-terminus: Met 1

**Molecular Characterization**

BCMA(Met 1 - Ala 54) Q02223-1	Poly-his
----------------------------------	----------

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 20.2 kDa.

**Conjugate**

PE

Excitation Wavelength: 488 nm / 561 nm

Emission Wavelength: 575 nm

**Formulation**Lyophilized from 0.22  $\mu$ m filtered solution in PBS, 0.2% BSA, pH7.4. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

**Reconstitution**

Please see Certificate of Analysis for specific instructions.

*For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.***Storage**For long term storage, the product should be stored at lyophilized state at  $-20^{\circ}\text{C}$  or lower.*Please protect from light and avoid repeated freeze-thaw cycles.*

This product is stable after storage at:

- $-20^{\circ}\text{C}$  to  $-70^{\circ}\text{C}$  for 12 months in lyophilized state;
- $-70^{\circ}\text{C}$  for 3 months under sterile conditions after reconstitution.


**Star Staining** fluorescent-labeled products are developed by a new-generation site-specific labeling technology with Star Standard quality at ACROBiosystems

★ Using new-generation site-specific labeling technology to maintain natural bioactivity.      ★ High specificity and sensitivity verified by flow cytometry.


★ No non-specific binding to non-transduced PBMCs.      ★ High homogeneity and high batch-to-batch consistency.

**Evaluation of CAR expression****FACS Analysis of Anti-BCMA CAR Expression**


A



B




C



5e5 of anti-BCMA CAR-293 cells were stained with 100  $\mu$ L of 1:50 dilution (2  $\mu$ L stock solution in 100  $\mu$ L FACS buffer) of PE-Labeled Human BCMA, His Tag (Cat. No. BCA-HP2H7) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).

**FACS Analysis of Non-specific binding to PBMCs**



5e5 of PBMCs were stained with PE-Labeled Human BCMA, His Tag (Cat. No. BCA-HP2H7) and anti-CD3 antibody, washed and then analyzed with FACS. FITC signal was used to evaluate the expression of CD3+ T cells in PBMCs, and PE signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).

### Background

Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.

### Clinical and Translational Updates

Please contact us via [TechSupport@acrobiosystems.com](mailto:TechSupport@acrobiosystems.com) if you have any question on this product.